1. |
Verma M. Pancreatic cancer epidemiology [J]. Technol Cancer Res Treat, 2005; 4(3)∶295.
|
2. |
Saif MW, Sviglin H, Carpenter M. Impact of ethnicity on outcome in pancreatic carcinoma [J]. JOP, 2005; 6(3)∶246.
|
3. |
Hahn SA, Bartsch DK. Genetics of hereditary pancreatic carcinoma [J]. Clin Lab Med, 2005; 25(1)∶117.
|
4. |
Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells [J]. Clin Cancer Res, 1999; 5(1)∶119.
|
5. |
Wang CY, Mayo MW, Korneluk RG, et al. NF-κB antiapoptotis: induction of TRAF1 and TARF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation [J]. Science, 1998; 281(5383)∶1680.
|
6. |
Zong WX, Bash J, Gelinas C. Rel blocks both anti-Fas- and TNF-induced apoptosis and intact Rel transactivation domain is essential for this effect [J]. Cell Death Differ, 1998;5(11)∶963.
|
7. |
Jeremias I, Kupatt C, Baumann B, et al. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells [J]. Blood, 1998; 91(12)∶4624.
|
8. |
Wang CY, Cusack JC, Liu R, et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB [J]. Nat Med, 1999; 5(4)∶412.
|
9. |
Wolff R A, Chiao P, Lenzi R, et al. Current approaches and future strategies for pancreatic carcinoma [J]. Investigational New Drugs, 2000; 18(1)∶43.
|
10. |
Sharma J, Srinivasan R, Majumdar S, et al. BCL-XL protein levels determine apoptotic index in pancreatic carcinoma [J]. Pancreas, 2005; 30(4)∶337.
|
11. |
Brazdil J, Lukas Z, Hermanova M, et al. Apoptosis and expression of bcl-2 protein in invasive ductal adenocarcinoma of the pancreas [J]. Cesk Patol, 2003; 39(4)∶168.
|
12. |
吴晓康, 吴育连, 郑樟栋, 等. 胰腺癌细胞凋亡与bcl-2,bax基因表达 [J]. 中国普通外科杂志, 2002; 11(3)∶171.
|
13. |
Kumar M , 刘正人, 田锐, 等. 生长抑素受体2基因转染抑制胰腺肿瘤细胞生长机制的探讨 [J]. 中华医学杂志, 2004; 84(9)∶760.
|
14. |
张元, 夏曙霞, 钱家勤. Bax 基因表达在胰腺癌组织细胞凋亡作用 [J]. 肝胆外科杂志, 2002; 10(5)∶344.
|
15. |
Yip-Schneider MT, Nakshatri H, Sweeney CJ, et al. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells [J]. Mol Cancer Ther, 2005; 4(4)∶587.
|
16. |
Muerkoster S, Arlt A, Sipos B, et al. Increased expression of the E3-ubiquitin ligase receptor subunit beta TRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells [J]. Cancer Res, 2005; 65(4)∶1316.
|
17. |
Muerkoster S, Arlt A, Witt M, et al. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer [J]. Int J Cancer, 2003; 104(4)∶469.
|
18. |
Fahy BN, Schlieman M, Virudachalam S, et al. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2 [J]. Br J Cancer, 2003; 89(2)∶391.
|
19. |
Saleem M, Kaur S, Kweon MH, et al. Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway [J]. Carcinogenesis, 2005; 26(11)∶1956.
|
20. |
Schneider G, Weber A, Zechner U, et al. GADD45alpha is highly expressed in pancreatic ductal adenocarcinoma cells and required for tumor cell viability [J]. Int J Cancer, 2006; 118(10)∶2405.
|
21. |
Trauzold A, Schmiedel S, Roder C, et al. Multiple and synergistic deregulations of apoptosis controling genes in pancreatic carcinoma cells [J]. Br J Cancer, 2003; 89(2)∶1714.
|
22. |
Mouria M, Gukovskaya AS, Jung Y, et al. Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis [J]. Int J Cancer, 2002; 98(5)∶761.
|